CAJ | 학술논문

目的：探讨白蛋白结合型紫杉醇联合贝伐珠单抗二线治疗晚期胰腺癌疗效、不良反应和生存情况。方法应用白蛋白结合型紫杉醇联合贝伐珠单抗二线治疗晚期胰腺癌27例，具体方案：第1天白蛋白结合型紫杉醇130 mg/ m2、贝伐珠单抗7.5 mg/ m2，21 d 为1个周期，最少化疗2个周期，每个周期评价不良反应，2个周期评价疗效。结果27例患者均可进行疗效评价，无完全缓解病例，部分缓解2例，稳定14例，进展11例，有效率为7.41%，临床获益率为59.26%，中位无进展生存期为4个月（95% CI 为3.004~4.996个月），中位生存期为8个月（95% CI 为5.900~10.100个月）。主要不良反应为骨髓抑制、胃肠道反应、乏力、脱发、皮疹及外周神经毒性，不良反应多为1~2级，患者能够耐受，未发生治疗相关性死亡。结论白蛋白结合型紫杉醇联合贝伐珠单抗二线治疗晚期胰腺癌可以控制病情进展，不良反应可以耐受，但仍需要扩大样本深入研究。
목적：탐토백단백결합형자삼순연합패벌주단항이선치료만기이선암료효、불량반응화생존정황。방법응용백단백결합형자삼순연합패벌주단항이선치료만기이선암27례，구체방안：제1천백단백결합형자삼순130 mg/ m2、패벌주단항7.5 mg/ m2，21 d 위1개주기，최소화료2개주기，매개주기평개불량반응，2개주기평개료효。결과27례환자균가진행료효평개，무완전완해병례，부분완해2례，은정14례，진전11례，유효솔위7.41%，림상획익솔위59.26%，중위무진전생존기위4개월（95% CI 위3.004~4.996개월），중위생존기위8개월（95% CI 위5.900~10.100개월）。주요불량반응위골수억제、위장도반응、핍력、탈발、피진급외주신경독성，불량반응다위1~2급，환자능구내수，미발생치료상관성사망。결론백단백결합형자삼순연합패벌주단항이선치료만기이선암가이공제병정진전，불량반응가이내수，단잉수요확대양본심입연구。
Objective To investigate the efficacy,adverse reaction and survival condition of albumin-bound paclitaxel combined with bevacizumab as second-line therapy in patients with advanced pancreatic cancer. Methods Twenty-seven cases of advanced pancreatic cancer were enrolled to receive albumin-bound paclitaxel combined with bevacizumab regimen. The dose of the drugs was as follows:albumin-bound paclitaxel 130 mg/ m2 ,d1,bevacizumab 7. 5 mg/ m2 ,d1. Twenty-one days were a cycle for each regimen,and the least chemotherapy cycle was 2. The adverse reactions were evaluated for each cycle and the objective response was evaluated for 2 cycles. Results The 27 patients could be evaluated. None was in complete remission,2 cases were in partial remission,14 cases were in stabilization,11 cases were in progress. The response rate(RR) was 7. 41% ,and the disease control rate(DCR)was 59. 26% . The median progress free survival(PFS)was 4 months(95% CI:3. 004-4. 996 months),and the median overall survival(OS)was 8 months(95% CI:5. 900-10. 100 months). The main adverse reactions included myelosuppression,gastrointestinal reaction, fatigue,lipsotrichia,erythra,peripheral neurotoxicity,etc,most of which were 1-2 grade. The adverse effect was well tolerated,and there was no treatment-related death. Conclusion The albumin-bound paclitaxel com-bined with bevacizumab as second-line therapy in patients with advanced pancreatic cancer shows slow progress and low adverse effect and needs further study.